Drug intelligence / Profile preview

Aloneb

Development stage: Phase 4
Lead developer: Istituto Lusofarmaco
Modality: Small Molecules
Administration: Oral

Overview

**Aloneb** is an approved oral fixed-dose combination antihypertensive product marketed by **Istituto Lusofarmaco d'Italia** for the treatment of **essential hypertension**. The product contains **nebivolol**, a selective beta-1 adrenergic receptor blocker with vasodilatory activity linked to nitric oxide pathways, and **hydrochlorothiazide**, a thiazide diuretic that lowers blood pressure by inhibiting renal sodium chloride reabsorption in the distal convoluted tubule. Together, the combination provides complementary blood-pressure-lowering effects through reduction of cardiac adrenergic drive and promotion of natriuresis/diuresis.

Brand names: Aloneb
Other names: nebivolol + hydrochlorothiazidenebivololo + idroclorotiazide

Targets

ADRB1 (β1)ADRB3 (β3)NOS3 (eNOS)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on Aloneb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aloneb.